Tapinarof

Pregnancy: There isn't enough data on Tapinarof cream in pregnant women to judge whether it carries a risk of major birth defects, miscarriage, or other harmful outcomes for the mother or the baby. In animal reproduction studies, Tapinarof was given under the skin (subcutaneously) to pregnant rats and rabbits during organogenesis. No significant adverse effects were seen at doses 268 and 16 times, respectively, the maximum recommended human dose (MRHD). The background risk of major birth defects and miscarriage in the people this medicine is meant for is unknown. Every pregnancy carries some background risk of major birth defects, loss, and other adverse outcomes.

Lactation: No data are available on whether Tapinarof passes into human milk, what it does to a breastfed infant, or whether it affects milk production. Tapinarof was found in rat offspring after pregnant female rats were given it subcutaneously, which suggests it was transferred into the milk of lactating rats. When a drug is present in animal milk, it is likely to be present in human milk too. So the developmental and health benefits of breastfeeding should be weighed together with the mother's clinical need for Tapinarof cream, and with any possible adverse effects on the breastfed infant, whether from Tapinarof cream or from the mother's underlying condition.